Scarica l'app Stockscreener
0.23
3.00%
0.0067
Dopo l'orario di chiusura:
.23
Precedente Chiudi:
$0.2233
Aprire:
$0.2233
Volume 24 ore:
174.05K
Relative Volume:
0.07
Capitalizzazione di mercato:
$2.33M
Reddito:
$2.88M
Utile/perdita netta:
$-5.12M
Rapporto P/E:
-0.000852
EPS:
-269.9888
Flusso di cassa netto:
-
1 W Prestazione:
+1.77%
1M Prestazione:
+2.50%
6M Prestazione:
-81.75%
1 anno Prestazione:
-96.35%
Intervallo 1D:
$0.2204
$0.23
Intervallo di 1 settimana:
$0.2106
$0.2554
Portata 52W:
$0.2055
$14.22
Scisparc Ltd Stock (SPRC) Company Profile
Scisparc Ltd Borsa (SPRC) Ultime notizie
SciSparc Ltd. Reports Changes in Financial Position - TipRanks
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
SciSparc Ltd. Gains Shareholder Approval for Proposals - TipRanks
SciSparc Ltd. Reschedules Annual General Meeting - TipRanks
Examining SPRC’s book value per share for the latest quarter - US Post News
Financial Metrics Unveiled: SciSparc Ltd (SPRC)’s Key Ratios in the Spotlight - The Dwinnex
SPRC Stock Hits 52-Week Low at $0.21 Amid Market Challenges - Investing.com
SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN
SciSparc stock plunges to 52-week low, hits $0.23 - Investing.com India
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome - 420 Intel
SciSparc receives FDA approval for trial for Tourette syndrome therapy - Clinical Trials Arena
SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN
FDA greenlights SciSparc's Phase IIb Tourette Syndrome study By Investing.com - Investing.com South Africa
Pharmaceutical FDA Next Phase Cannabinoid For TouretteSciSparc (NASDAQ:SPRC) - Benzinga
SciSparc secures FDA approval to launch Phase IIB trial for TS treatment - TipRanks
FDA greenlights SciSparc's Phase IIb Tourette Syndrome study - Investing.com
SciSparc Secures FDA Green Light to US Launch of its - GlobeNewswire
Financial Metrics Check: SciSparc Ltd (SPRC)’s Ratios for Trailing Twelve Months - The Dwinnex
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - StockTitan
SciSparc Ltd (SPRC) stock: A year of ups and downs - US Post News
SciSparc signs LOI to sell entire ownership in MitoCareX - MSN
SciSparc Ltd. Proposes Reverse Stock Split - TipRanks
SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Canada
SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com
SciSparc Announces Intent to Sell MitoCareX Stake - TipRanks
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewswire
Holdings of SciSparc Ltd (SPRC) are aligned with the stars - SETE News
Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World
Smartgroup Announces Major Shareholding Changes - TipRanks
Science Group PLC Executes Share Buyback - TipRanks
Site Group Plans Massive New Share Issue - TipRanks
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World
Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily
SIGA Technologies (NASDAQ:SIGA) Shares Down 2.4% - MarketBeat
CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - TipRanks
Smiths Group results: Could the share price sell-off present an opportunity? - Investors Chronicle
SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts
Clearmind, SciSparc slide amid weight-loss study results - MSN
FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter
UBS Cuts Stake in Spirent Communications - TipRanks
SThree maintains expectations amid tough market conditions. - Research the market
UK recruiter SThree falls on lower Q3 net fee - XM
SThree says UK the worst performer as recruitment fees drop - Proactive Investors UK
Science Group PLC Announces Share Buyback - TipRanks
SThree plc Navigates Market Headwinds in Q3 - TipRanks
SThree Net Fees Fall Amid Challenging Environment - MarketWatch
Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.
100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World
SciSparc Ltd Inc. (SPRC) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat
Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World
Scisparc Ltd Azioni (SPRC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):